Total Payments
$461.91
2024 Payments
$243.58
Companies
4
Transactions
25
Medicare Patients
1,215
Medicare Billing
$67,706
Payment Breakdown by Category
Food & Beverage$461.91 (100.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $461.91 | 25 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $261.18 | 12 | $0 (2024) |
| Genentech USA, Inc. | $106.81 | 11 | $0 (2022) |
| Supernus Pharmaceuticals, Inc. | $71.97 | 1 | $0 (2023) |
| ITI, Inc. | $21.95 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $243.58 | 11 | ABBVIE INC. ($243.58) |
| 2023 | $111.52 | 3 | Supernus Pharmaceuticals, Inc. ($71.97) |
| 2022 | $17.75 | 2 | Genentech USA, Inc. ($17.75) |
| 2021 | $89.06 | 9 | Genentech USA, Inc. ($89.06) |
All Payment Transactions
25 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/11/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $8.44 | General |
| Category: NEUROSCIENCE | ||||||
| 11/08/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $8.57 | General |
| Category: NEUROSCIENCE | ||||||
| 10/30/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $14.37 | General |
| Category: NEUROSCIENCE | ||||||
| 10/14/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $12.71 | General |
| Category: NEUROSCIENCE | ||||||
| 09/25/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $7.92 | General |
| Category: NEUROSCIENCE | ||||||
| 08/20/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $12.35 | General |
| Category: NEUROSCIENCE | ||||||
| 08/15/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $15.33 | General |
| Category: NEUROSCIENCE | ||||||
| 07/30/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $7.28 | General |
| Category: NEUROSCIENCE | ||||||
| 04/04/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $17.82 | General |
| Category: NEUROSCIENCE | ||||||
| 02/08/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $15.36 | General |
| Category: NEUROSCIENCE | ||||||
| 01/22/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $123.43 | General |
| Category: NEUROSCIENCE | ||||||
| 08/09/2023 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $17.60 | General |
| Category: NEUROSCIENCE | ||||||
| 08/03/2023 | Supernus Pharmaceuticals, Inc. | QELBREE (Drug) | Food and Beverage | In-kind items and services | $71.97 | General |
| Category: PSYCHOLOGY | ||||||
| 02/28/2023 | ITI, Inc. | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $21.95 | General |
| Category: PSYCHIATRY | ||||||
| 03/03/2022 | Genentech USA, Inc. | Xofluza (Drug) | Food and Beverage | In-kind items and services | $14.94 | General |
| Category: Virology & Specialty Care | ||||||
| 02/22/2022 | Genentech USA, Inc. | Xofluza (Drug) | Food and Beverage | In-kind items and services | $2.81 | General |
| Category: Virology & Specialty Care | ||||||
| 12/28/2021 | Genentech USA, Inc. | Xofluza (Drug) | Food and Beverage | In-kind items and services | $17.77 | General |
| Category: Virology & Specialty Care | ||||||
| 12/07/2021 | Genentech USA, Inc. | Xofluza (Drug) | Food and Beverage | In-kind items and services | $12.64 | General |
| Category: Virology & Specialty Care | ||||||
| 11/09/2021 | Genentech USA, Inc. | Xofluza (Drug) | Food and Beverage | In-kind items and services | $16.87 | General |
| Category: Virology & Specialty Care | ||||||
| 10/27/2021 | Genentech USA, Inc. | Xofluza (Drug) | Food and Beverage | In-kind items and services | $10.39 | General |
| Category: Virology & Specialty Care | ||||||
| 10/27/2021 | Genentech USA, Inc. | Xofluza (Drug) | Food and Beverage | In-kind items and services | $4.58 | General |
| Category: Virology & Specialty Care | ||||||
| 03/09/2021 | Genentech USA, Inc. | Xofluza (Drug) | Food and Beverage | In-kind items and services | $4.17 | General |
| Category: Virology & Specialty Care | ||||||
| 03/02/2021 | Genentech USA, Inc. | Xofluza (Drug) | Food and Beverage | In-kind items and services | $1.68 | General |
| Category: Virology & Specialty Care | ||||||
| 02/13/2021 | Genentech USA, Inc. | Xofluza (Drug) | Food and Beverage | In-kind items and services | $11.22 | General |
| Category: Virology & Specialty Care | ||||||
| 02/02/2021 | Genentech USA, Inc. | Xofluza (Drug) | Food and Beverage | In-kind items and services | $9.74 | General |
| Category: Virology & Specialty Care | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 273 | 297 | $47,520 | $12,692 |
| 2022 | 7 | 335 | 387 | $60,675 | $20,860 |
| 2021 | 8 | 352 | 504 | $59,995 | $20,186 |
| 2020 | 8 | 255 | 270 | $48,535 | $13,969 |
Total Patients
1,215
Total Services
1,458
Medicare Billing
$67,706
Procedure Codes
32
All Medicare Procedures & Services
32 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 90 | 90 | $21,600 | $5,207 | 24.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 55 | 56 | $13,440 | $3,720 | 27.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 22 | 23 | $5,175 | $1,301 | 25.1% |
| 87811 | Detection test by immunoassay with direct visual observation for severe acute respiratory syndrome coronavirus 2 (covid-19) | Office | 2023 | 20 | 20 | $1,600 | $811.00 | 50.7% |
| 87804 | Detection test by immunoassay with direct visual observation for influenza virus | Office | 2023 | 21 | 42 | $2,100 | $681.24 | 32.4% |
| 87426 | Detection test by immunoassay technique for severe acute respiratory syndrome coronavirus | Office | 2023 | 14 | 14 | $1,120 | $484.68 | 43.3% |
| 87880 | Detection test by immunoassay with direct visual observation for streptococcus, group a (strep) | Office | 2023 | 13 | 14 | $700.00 | $226.80 | 32.4% |
| 71046 | X-ray of chest, 2 views | Office | 2023 | 12 | 12 | $1,005 | $202.84 | 20.2% |
| 81003 | Automated urinalysis test | Office | 2023 | 26 | 26 | $780.00 | $57.20 | 7.3% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 77 | 77 | $18,480 | $5,580 | 30.2% |
| 87426 | Detection test by immunoassay technique for severe acute respiratory syndrome coronavirus | Office | 2022 | 94 | 100 | $8,000 | $4,258 | 53.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 61 | 71 | $15,975 | $3,997 | 25.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 31 | 33 | $7,920 | $3,046 | 38.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 20 | 20 | $6,000 | $2,577 | 42.9% |
| 87804 | Detection test by immunoassay with direct visual observation for influenza virus | Office | 2022 | 34 | 68 | $3,400 | $1,111 | 32.7% |
| 87880 | Detection test by immunoassay with direct visual observation for streptococcus, group a (strep) | Office | 2022 | 18 | 18 | $900.00 | $292.25 | 32.5% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Office | 2021 | 101 | 101 | $24,240 | $8,068 | 33.3% |
| 87426 | Elisa detection of severe acute respiratory syndrome coronavirus 2 (covid-19) antigen | Office | 2021 | 111 | 126 | $10,080 | $5,699 | 56.5% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 69 | 84 | $18,900 | $4,892 | 25.9% |
| 87804 | Detection test by immunoassay for influenza virus | Office | 2021 | 22 | 44 | $2,200 | $728.20 | 33.1% |
| 99202 | New patient outpatient visit, total time 15-29 minutes | Office | 2021 | 11 | 11 | $2,475 | $663.30 | 26.8% |
| 96372 | Injection beneath the skin or into muscle for therapy, diagnosis, or prevention | Office | 2021 | 15 | 16 | $640.00 | $97.54 | 15.2% |
| 81003 | Automated urinalysis test | Office | 2021 | 11 | 12 | $360.00 | $27.00 | 7.5% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2021 | 12 | 110 | $1,100 | $10.65 | 1.0% |
| 99203 | New patient office or other outpatient visit, typically 30 minutes | Office | 2020 | 100 | 100 | $24,000 | $6,743 | 28.1% |
About Nicholas Glaze, NP
Nicholas Glaze, NP is a Nurse Practitioner healthcare provider based in Cedar Hill, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/18/2013. The National Provider Identifier (NPI) number assigned to this provider is 1255767513.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Nicholas Glaze, NP has received a total of $461.91 in payments from pharmaceutical and medical device companies, with $243.58 received in 2024. These payments were reported across 25 transactions from 4 companies. The most common payment nature is "Food and Beverage" ($461.91).
As a Medicare-enrolled provider, Glaze has provided services to 1,215 Medicare beneficiaries, totaling 1,458 services with total Medicare billing of $67,706. Data is available for 4 years (2020–2023), covering 32 distinct procedure/service records.
Ad
Practice Information
- Specialty Nurse Practitioner
- Other Specialties Family
- Location Cedar Hill, TX
- Active Since 09/18/2013
- Last Updated 09/20/2024
- Taxonomy Code 363L00000X
- Entity Type Individual
- NPI Number 1255767513
Products in Payments
- VRAYLAR (Drug) $261.18
- Xofluza (Drug) $106.81
- QELBREE (Drug) $71.97
- CAPLYTA (Drug) $21.95
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.